hydroxychloroquine has been researched along with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase II selection design will be used to determine hdroxychloroquine's efficacy, using prednisolone dosage and Birmingham Vasculitis Activity Score as a measure of disease activity." | 3.30 | The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. ( Arnold, L; Beckley-Hoelscher, N; Cape, A; Casian, A; D'Cruz, D; Douiri, A; Galloway, J; Jayne, D; John, S; Kim, S; Learoyd, AE; Luqmani, R; Morton, N; Nel, L; Reid, F; Sangle, S; Shivapatham, D, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Learoyd, AE | 1 |
| Arnold, L | 1 |
| Reid, F | 1 |
| Beckley-Hoelscher, N | 1 |
| Casian, A | 1 |
| Sangle, S | 1 |
| Morton, N | 1 |
| Nel, L | 1 |
| Cape, A | 1 |
| John, S | 1 |
| Kim, S | 1 |
| Shivapatham, D | 1 |
| Luqmani, R | 1 |
| Jayne, D | 2 |
| Galloway, J | 1 |
| Douiri, A | 1 |
| D'Cruz, D | 1 |
| Kronbichler, A | 1 |
1 trial available for hydroxychloroquine and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
| Article | Year |
|---|---|
The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
1 other study available for hydroxychloroquine and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
| Article | Year |
|---|---|
Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cytoplasm; Humans; Hydroxychloroquine; I | 2020 |